Shots:
- Welcome to the 2025 edition of Know Your Investor, highlighting leading venture capital firms shaping the future of healthcare innovation
- This edition highlights Invus, an investment firm focused on supporting life sciences companies committed to advancing breakthroughs that enhance public health
- In 2024, Invus invested around $4.15B across six funding rounds, expanding its portfolio with 31 new healthcare and biotech investments. For the complete report, reach out to us at connect@pharmashots.com.
Founded in 1985, Invus is an investment company with a presence in New York, Paris, and Hong Kong. Ever since the company started, the source of funding remained a European family group. With its evergreen investment approach, Invus’ small initial pool of funds expanded to nearly $10B. The company partners with owner-managers and invests across a wide spectrum of companies, ranging from early-stage growth to turnarounds, with initial investments ranging from $10M to $800M. The company participates in both major and minor investments.
In 2024, Invus participated in six funding rounds across various stages, including PIPE and Series A-E. Notable additions to its portfolio include:
- Lexicon Pharmaceuticals
- Bright Peak Therapeutics
- Scorpion Therapeutics
- Ottimo Pharma
The firm’s largest single investment was a $400M Series A funding in Mirador Therapeutics.
Invus invests across a broad range of sectors, including consumer goods, food, specialty retail, software, biotech, medical devices, and professional services. The firm targets companies at various stages of growth and development, applying a flexible investment approach backed by deep international expertise. Its global portfolio emphasizes opportunities in the United States, Europe, China, and India, reflecting its broad geographic reach and adaptable strategy.
Therapeutic Areas of Focus:
- Oncology
- Infectious diseases
- Neurology
- Immunology
- Genitourinary
- Hepatology
- Pulmonology
- Cardiology
Technological Focus:
- Antibodies
- Small molecules
- Cell and gene therapies
- Immunotherapies
- Peptides
- Antibody conjugates
- Diagnostic Devices
In 2024:
- Invested in 31 companies
- 32.2% of investments were through PIPE Funding
- 22.5% were through Series A
Key Investments in 2024:
- $400M Series A - Mirador Therapeutics
- $350M PIPE - Crinetics Pharmaceutical
- $280M PIPE - Cullinan Oncology
Quarterly Investments in 2024:
- Q1: 9 investments worth $1541M
- Q2: 8 investments worth $931.8M
- Q3: 4 investments worth $640M
- Q4: 10 investments worth $1039.9M
The table below depicts the top 5 out of the 31 investments made by Invus:
Note: (For a complete report, reach out to us at connect@pharmashots.com with the subject line “Invus” or for early access to complete data for future reports and analysis, register here: https://forms.office.com/r/VwFu6aUm80)
Related Post: Know Your Investor: Invus (July’24 Edition)
